“A double-blind, placebo-controlled, clinical trial of dehydroepiandrosterone in severe systemic lupus erythematosus”, van Vollenhoven et al., 1999, 8(3), 181-187.* |
Alcocer-Varela et al., J. Clin. Invest. 69:1388-1392 (Jun. 1982). |
Barrett-Connor et al., New Engl. J. Med. 315:1519-1524 (1986). |
Bombardier et al., & The Committee on Prognosis Studies in SLE “Derivation of SLEDAI. A disease activity index for lupus patients.,” Arthritis Rheum. 35:630-640 (Jun. 1992). |
Gutierrez-Ramos et al., Nature 346:271-274 (Jul. 1990). |
Hawker et al., “A reliability study of SLEDAI: a disease activity index for systemic lupus erythematosus,” J. Rheumatol. 20:4:657-660 (Apr. 1993). |
Heinz, D. et al., Steroids Lip Res. 5(223):216-223 (1974). |
Jungers et al., Arthritis Rheum. 25:4:454-457 (Apr. 1982). |
Kaki, A.M. and Lewis, G.W., “Inguinal paravascular (lumbar plexus) Neurolytic Block—Description of a Catheter Technique: case report,” Reg. Anesth. Pain. Med. 23:2:214-218 (Mar.-Apr. 1998). |
Krupp, L.B. et al., “The Fatigue Severity Scale: Application to Patients with Multiple Sclerosis and Systemic Lupus Erythematosus” Arch Neurol. 46:1121-1123 (1989). |
Lahita et al., “Increased Oxidation of Test Osterone in Systemic Lupus Erythematosus” Arthritis Rheum. 26:1517 (1983). |
Liang et al., “Reliability and Validity of Six Systems for the Clinical Assessment of Disease Activity in Systemic Lupus Erythematosus” Arthritis Rheum. 32:9:1107-1118 (1989). |
Linker-Israeli et al., J. Immunol. 130:6:2651-2655 (Jun. 1983). |
Lucas et al., “Prevention of Autoantibody Formation and Prolonged Survival in New Zealand Black/New Zealand White F1 Mice Fed Dehydroisoandrosterone” J. Clin. Invest. 75:2091-2093 (Jun. 1985). |
Morand et al., “Fibromyalgia syndrome and disease activity in systemic lupus erythematosus,” Lupus 3:187-191 (Jun. 1994). |
Murakawa et al., “Characterization of T Lymphocyte Subpopulations Responsible for Deficient Interleukin 2 Activity in Patients with Systemic Lupus Erythematosus” J. Immunol. 134:1:187-195 (Jan. 1985). |
Roubinian et al., “Danazol's Failure to Suppress Autoimmunity in NZB/NZW F1 Mice” Arthritis Rheum. 22:12:1399-1402 (Dec. 1979). |
Shafer et al., “Preoperative anxiety and fear: a comparison of assessements by patients and anesthesia and surgery residents,” Anesth. Analg. 83:1285-1291 (1996). |
Sheean et al., “An open-labelled clinical and electrophysical study of 3,4 diaminopyridine in the treatment of fatigue in multiple sclerosis,” Brain 121:967-975 (1998). |
Singer et al., “Comparison of patient and practioner assessments of pain from commonly performed emergency department procedures,” Ann. Emerg. Med. 33:6:652-658 (Jun. 1999). |
Singer et al., “Determination of the minimal clinically significant difference on a patient visual analog satisfaction scale,” Acad. Emerg. Med. 5:10:1007-1011 (Oct. 1998). |
Steinberg et al., “Approach to the Study of the Role of Sex Hormones in Autoimmunity” Arthritis Rheum. 22:11:1170-1176 (Nov. 1979). |
Vande Wiele et al., “Studies on the Secretion and Interconversion of the Androgens” Recent Prog. Horm. Res. 19:275-310 (1963). |
Mease, P.J. (reprint) et al. “GL701 (prasterone, dehydroeplandrosterone) improves systemic lupus erythematosus.” Arthritis and Rheumatism, (Sep. 2000) vol. 43, No. 9, Supp. 'SI, pp. 1230-1230. Publisher: Lippincott Williams & Wilkins, 530 Walnut St., Philadelphia, PA 19106-3621. ISSN: 0004-3591., XP001039585. |
Database Phin 'Online! Scrip (1999) No. 2493 p20, Nov. 26, 1999 “GeneLabs nears lupus NDA filling” retrieved from STN Database accession No. 1999: 20570 XP002182026 abstract. |
Barry, N. N. et al: “Dehydroeplandrosterone in systemic lupus erythematosus: relationship between dosage, serum levels, and clinical response.” Journal of Rheumatology, (Dec. 1998) 25 (12) 2352-6. XP001039566. |
Database Phin 'Online! Scrip (1999) No. 2476, p27, Sep. 29, 1999 “Positive results in SLE from Genelabs” retrieved from STN Database accession No. 1999:16620 XP002182027. |
Van Vollenhoven R F et al.: Treatment of systemic lupus erythematosus with dehydroepiandrosterone: 50 patients treated up to 12 months. Journal of Rheumatology, (Feb. 1998) 25 (2) 285-9 xp001039567. |
Van Vollenhoven R F et al. “Dehydroepiandrosterone in systemic lupus erythematosus. Results of a double-blind, placebo-controlled, randomized clinical trial.” Arthritis and Rheumatism, (Dec. 1995) 38 (12) 1826-31, XP001039561. |
Database Phin 'Online! Scrip (1997) No. 2228 p20, “Genelab's DHEA ineffective in systemic lupus erythematosus (SLE)” retrieved from STN Database accession No. 97:8552 XP002182028. |
Chang, et al: “Solid State Characterization of Dehydroepiandrosterone” Journal of Pharaceutical Sciences. American Pharmaceutical Association. Washington, US, vol. 84, No. 10, 1995, pp. 1169-1179, XP002148232 ISSN:0022-3549. |